Skin, hair & aesthetics

GHK-Cu

Name: GHK-Cu: What the Research Actually Shows
Creator: Peptide Health Lab

FOR RESEARCH PURPOSES ONLY

Also known as: Copper tripeptide-1, GHK, Glycyl-L-histidyl-L-lysine, Copper peptide

Regulatory status: Research only
Evidence grade: Animal studies only

Last reviewed August 2, 2026 · 17 sources

What GHK-Cu is and how it works

GHK is a chain of three amino acids (glycine, histidine, and lysine) that occurs naturally in human plasma, saliva, and urine.^[15] It was originally isolated from human plasma and identified by its unusually high affinity for copper(II); the complex it forms with that ion is what the literature calls GHK-Cu, and it is the blue color of bound copper that gives the lyophilized powder its appearance.^[1]

The observation that started the field is narrow and specific. In fibroblast culture, GHK-Cu stimulated collagen synthesis at concentrations beginning between a picomolar and ten picomolar, peaking around a nanomolar, with no change in cell number. The cells were making more collagen rather than simply multiplying.^[1] The authors noted that a GHK triplet exists inside the alpha-2 chain of type I collagen itself, and proposed that proteases liberate the tripeptide at the site of an injury, where it acts locally as a repair signal.^[1]

The mechanism proposed since then is not a single receptor. Reviews describe GHK as a copper-delivery molecule and a broad modulator: it moves copper into cells, influences matrix metalloproteinase expression and activation, shifts proteoglycan synthesis, and is described as antioxidant and anti-inflammatory.^[7]^[12] A later strand of that argument is genomic rather than biochemical: analyses using public gene-expression databases report that GHK shifts expression across thousands of genes toward patterns the authors characterize as healthy.^[14]^[13]

One finding complicates the whole copper story. When copper-free GHK was tested in keratinocyte cultures and reconstructed skin models, it produced effects similar to the copper complex.^[11] If the peptide works without its metal, then the mechanistic account that treats copper delivery as the point is at least incomplete.

What the research actually shows

Cell culture. This is the deepest layer. Beyond the original collagen result, GHK-Cu stimulated matrix metalloproteinase-2 expression by fibroblast cultures,^[3] and a combination experiment with hyaluronic acid reported upregulation of collagen types I, IV, and VII in human dermal fibroblasts and increased collagen IV in an explanted-skin model.^[16] In keratinocyte and skin-equivalent models, GHK increased proliferation and integrin expression at the basement membrane.^[11]

Rodent wounds. The most substantial in vivo work comes from a French group using implanted wound chambers in Sprague-Dawley rats. Serial injection of 2 mg GHK-Cu increased chamber tissue dry weight and total protein, raised type I collagen and glycosaminoglycan content, increased decorin messenger RNA while decreasing biglycan, and shifted the timing of gelatinase expression during late remodeling.^[4]^[2] A separate group created full-thickness wounds inside ischemic skin flaps on rats and found that topical tripeptide-copper gel closed wounds faster than vehicle or no treatment and lowered tumor necrosis factor alpha and gelatinase concentrations in biopsied tissue.^[5]

Systemic models. A computational screen across lung tissue sampled from regions of differing emphysema severity within the same lungs identified GHK as a compound predicted to reverse the destruction-associated gene signature; treating human lung fibroblasts with GHK reproduced a transforming growth factor beta expression pattern and restored collagen contraction in cells taken from COPD lungs.^[10] More recently, GHK-Cu at 0.2 and 2 mg/kg reduced smoke-induced muscle mass loss in mice through a sirtuin 1-dependent pathway, and plasma GHK measured lower in a small group of patients with COPD than in age-matched controls.^[15]

Delivery. A diffusion-cell experiment on isolated human skin measured how much copper actually crosses. Applied as 0.68% aqueous copper tripeptide under infinite-dose conditions, roughly 136 µg of copper per square centimetre permeated dermatomed skin over 48 hours with a further 97 µg per square centimetre retained as a depot.^[8] That is a real permeation number, and it came from a laboratory rig rather than a face.

Where the evidence is weak

This is the section that matters most, and for GHK-Cu it is unusually stark.

The controlled human evidence is essentially absent. A 2025 review written specifically to ask whether topical GHK works as an anti-wrinkle ingredient concluded that cellular studies support the idea but that there is a surprising absence of clinical studies using GHK-Cu and its palmitoylated derivative.^[17] For a compound that has been sold in cosmetics for decades, that is a large gap, and it is the single most important fact on this page.

Decades of use is not evidence. GHK-Cu's commercial history is long enough that its familiarity reads as validation. It is not. The absence of trials is not a sign that the question was settled early; it is a sign the question was never asked in a form that could produce an answer.

The review literature is concentrated. A large share of the syntheses that frame GHK as a broad regenerative and anti-aging agent come from the same small group, whose institutional affiliation on those papers is a commercial skin-care research company.^[9]^[13]^[14] That does not make the underlying observations wrong, and the disclosure is published in the papers themselves. It does mean the field lacks the independent replication normally expected before a compound is taken seriously.

Gene-expression analyses are hypotheses, not results. Two of the broadest claims are nervous-system benefit and reversal of age-related expression patterns. Both rest on database analyses of what GHK does to transcription in cells.^[13] A shifted expression signature is a reason to run an experiment, not a substitute for one.

Delivery is unresolved. Reviews describe the peptide as hydrophilic and poorly partitioning, with permeability that varies with derivative and enhancement method.^[17] For an injected route there is no human pharmacokinetic study at all.

Long-term safety is unknown. The animal studies were designed to detect wound-healing effects over days to weeks. Nothing in the published record speaks to repeated systemic copper delivery in people over months or years.

Legal and regulatory status

GHK-Cu is not approved by the FDA as a drug for any indication. Its long-standing presence in cosmetics is a separate regulatory track: cosmetic ingredients in the United States are not reviewed for efficacy before marketing, and the review literature is explicit that GHK-Cu is widely used in anti-wrinkle products without the clinical studies that would support a therapeutic claim.^[17]

Injectable GHK-Cu occupies a different position again. There is no approved injectable drug product containing this peptide, no assigned indication, and no regulated manufacturing standard for material labeled for laboratory research use, which is why every mention of it on this site carries research-only framing.

PHL does not sell peptides and takes no position on how unapproved material reaches anyone. What the regulatory status means for a reader is narrower and more useful: for the injected route there is no label, no approved manufacturer, no assigned indication, and no quality standard behind anything labeled GHK-Cu.^[14]

Questions to bring to a provider

The useful version of this conversation is not "should I use copper peptides." It is "here is the skin, hair, or healing outcome I actually care about. What has evidence behind it, and where does a cosmetic-history peptide with no trials sit relative to that?" Questions worth raising:

Is the concern photoaging, scarring, hair density, or a slow wound, and what does the standard-of-care evidence base offer for it?
Given that the entire efficacy literature is cell culture and rodent work, what would have to be true for an injected form to be worth considering at all?^[17]
Does a copper-handling disorder, liver or kidney impairment, or Wilson's disease in the family change how repeated copper delivery should be thought about?^[8]
Given that the mechanism is broad tissue remodeling and vessel recruitment, does a history of keloid formation, fibrosis, or malignancy change the calculus?^[10]
Would photography under fixed conditions, standardized hair counts, or wound-area tracing make it possible to tell whether anything actually changed?

A clinician who says "the trials that would answer this have not been run" is giving an accurate answer, not a dismissive one.

Evidence by claim

Grades describe how strong the evidence is; the line under each grade describes what kind of studies it is. How we grade evidence.

Collagen and extracellular-matrix synthesis in cell culture

Animal studies only in vitro

The founding observation is that GHK-Cu stimulated collagen synthesis in fibroblast cultures at picomolar to nanomolar concentrations, independent of any change in cell number. Later cell work reported stimulation of matrix metalloproteinase-2 expression by fibroblasts and, in a combination experiment, upregulation of collagen IV in dermal fibroblasts and an ex vivo skin model. All of it is cell-culture or explanted-tissue work.

[1] [3] [16]

Wound healing in animal models

Animal studies only animal

In rat wound chambers, repeated GHK-Cu injection increased wound tissue dry weight and total protein, raised type I collagen and glycosaminoglycan content, shifted decorin and biglycan expression, and altered matrix metalloproteinase expression during later remodeling. In a rat ischemic open-wound model, topical tripeptide-copper complex accelerated wound-area closure and lowered tissue tumor necrosis factor alpha and gelatinase levels versus untreated controls.

[2] [4] [5]

Epidermal stem-cell and keratinocyte behavior in skin-equivalent models

Animal studies only in vitro · review

In cultured normal human keratinocytes and reconstructed skin-equivalent models, GHK increased keratinocyte proliferation, produced more cuboidal basal cells, and increased integrin and p63 staining at the basement membrane. The study found copper-free GHK produced effects similar to the copper complex, which complicates the assumption that the copper is what does the work.

[11] [12]

Wrinkle reduction or measurable skin rejuvenation in humans

Anecdotal reports only review

No published randomized controlled trial establishes that topical or injected GHK-Cu reduces wrinkles or improves any objective measure of skin aging. A 2025 review dedicated to exactly this question concludes that although cellular studies support the ingredient, there is a surprising absence of clinical studies using GHK-Cu and its derivatives. The claim is graded on the strength of what exists, which is cell data and marketing history, not trial data.

[17] [12]

Hair growth

Anecdotal reports only in vitro · review

The primary study most often cited for copper-peptide hair effects tested AHK-Cu (alanyl-histidyl-lysine-copper), a different tripeptide, and reported elongation of explanted human hair follicles and proliferation of cultured dermal papilla cells in vitro. That result does not transfer to GHK-Cu by assumption, and no controlled human trial of GHK-Cu for hair loss is published. The honest position is that this claim area has no direct evidence for this compound.

[6] [12]

Systemic, pulmonary, and muscle effects

Animal studies only in vitro · animal

A computational screen of lung tissue from smokers with COPD identified GHK as a compound that reversed the gene-expression signature of emphysematous destruction, and treating human lung fibroblasts with GHK reproduced a transforming growth factor beta expression pattern and restored collagen contraction. Separately, GHK-Cu rescued smoke-induced skeletal muscle dysfunction in mice through a sirtuin 1-dependent pathway, and lower plasma GHK was measured in a small group of patients with COPD than in age-matched controls.

[10] [15]

Anti-aging, antioxidant, and nervous-system effects

Animal studies only review

A series of review and gene-expression analyses argue that GHK resets pathological expression patterns toward health across many tissues, including nervous-system and cognitive-decline pathways. These are literature syntheses and database analyses rather than experiments in animals or people, and they originate almost entirely from one group.

[9] [13] [14] [7]

Claim area	Evidence & sources	What the research shows
Collagen and extracellular-matrix synthesis in cell culture	Animal studies only in vitro [1] [3] [16]	The founding observation is that GHK-Cu stimulated collagen synthesis in fibroblast cultures at picomolar to nanomolar concentrations, independent of any change in cell number. Later cell work reported stimulation of matrix metalloproteinase-2 expression by fibroblasts and, in a combination experiment, upregulation of collagen IV in dermal fibroblasts and an ex vivo skin model. All of it is cell-culture or explanted-tissue work.
Wound healing in animal models	Animal studies only animal [2] [4] [5]	In rat wound chambers, repeated GHK-Cu injection increased wound tissue dry weight and total protein, raised type I collagen and glycosaminoglycan content, shifted decorin and biglycan expression, and altered matrix metalloproteinase expression during later remodeling. In a rat ischemic open-wound model, topical tripeptide-copper complex accelerated wound-area closure and lowered tissue tumor necrosis factor alpha and gelatinase levels versus untreated controls.
Epidermal stem-cell and keratinocyte behavior in skin-equivalent models	Animal studies only in vitro · review [11] [12]	In cultured normal human keratinocytes and reconstructed skin-equivalent models, GHK increased keratinocyte proliferation, produced more cuboidal basal cells, and increased integrin and p63 staining at the basement membrane. The study found copper-free GHK produced effects similar to the copper complex, which complicates the assumption that the copper is what does the work.
Wrinkle reduction or measurable skin rejuvenation in humans	Anecdotal reports only review [17] [12]	No published randomized controlled trial establishes that topical or injected GHK-Cu reduces wrinkles or improves any objective measure of skin aging. A 2025 review dedicated to exactly this question concludes that although cellular studies support the ingredient, there is a surprising absence of clinical studies using GHK-Cu and its derivatives. The claim is graded on the strength of what exists, which is cell data and marketing history, not trial data.
Hair growth	Anecdotal reports only in vitro · review [6] [12]	The primary study most often cited for copper-peptide hair effects tested AHK-Cu (alanyl-histidyl-lysine-copper), a different tripeptide, and reported elongation of explanted human hair follicles and proliferation of cultured dermal papilla cells in vitro. That result does not transfer to GHK-Cu by assumption, and no controlled human trial of GHK-Cu for hair loss is published. The honest position is that this claim area has no direct evidence for this compound.
Systemic, pulmonary, and muscle effects	Animal studies only in vitro · animal [10] [15]	A computational screen of lung tissue from smokers with COPD identified GHK as a compound that reversed the gene-expression signature of emphysematous destruction, and treating human lung fibroblasts with GHK reproduced a transforming growth factor beta expression pattern and restored collagen contraction. Separately, GHK-Cu rescued smoke-induced skeletal muscle dysfunction in mice through a sirtuin 1-dependent pathway, and lower plasma GHK was measured in a small group of patients with COPD than in age-matched controls.
Anti-aging, antioxidant, and nervous-system effects	Animal studies only review [9] [13] [14] [7]	A series of review and gene-expression analyses argue that GHK resets pathological expression patterns toward health across many tissues, including nervous-system and cognitive-decline pathways. These are literature syntheses and database analyses rather than experiments in animals or people, and they originate almost entirely from one group.

FOR RESEARCH PURPOSES ONLY

Typical protocol range in the research

Cultured human skin fibroblasts: the concentration range at which the original collagen-synthesis effect was observed in vitro

Stimulation began between 10^-12 and 10^-11 M and was maximal at 10^-9 M [1]
Rat wound-chamber studies: the amount injected into implanted wound chambers in the Reims wound-healing model

2 mg per injection, repeated on a serial schedule across the study [2] [4]
Mouse model of cigarette-smoke-induced skeletal muscle dysfunction

0.2 and 2 mg/kg of mouse body weight [15]
Topical application to isolated human skin in a laboratory diffusion cell, a permeation measurement rather than a treatment schedule

0.68% aqueous copper tripeptide applied under infinite-dose conditions over 48 hours [8]
Humans, any cosmetic or medical outcome

No published clinical trial establishes a topical or injected amount for any outcome; a 2025 review of topical GHK describes a surprising absence of clinical studies using GHK-Cu [17]

Only the first four entries have a published source behind them, and each is a laboratory or rodent figure: a molar concentration in a culture dish, an amount injected into an implanted chamber in a rat, a per-kilogram mouse dose, and a percentage in a diffusion cell. None of them is a human protocol, and none translates into one.

Ranges are what published research reports, not a recommendation. PHL does not prescribe, and nothing here is personalized to you.

Side effects & safety signals

No established human safety profile for injected or topical GHK-Cu

Not established · Unknown. This is an absence of data, not a finding of safety. A 2025 review of GHK as a topical anti-wrinkle ingredient reports that despite wide cosmetic use, published clinical studies using GHK-Cu are largely missing, which means tolerability has not been characterized in a controlled human setting.

[17] [14]
Copper delivery is the mechanism, and copper is the exposure

Quantified in vitro, not in people · GHK-Cu is a copper carrier by design. In a laboratory diffusion-cell experiment, 0.68% aqueous copper tripeptide delivered roughly 136 µg of copper per square centimetre through dermatomed human skin over 48 hours, with a further depot retained in the tissue. What repeated systemic copper loading means for a person with a disorder of copper handling, or with hepatic or renal impairment, has not been studied, and is a reason to raise the compound with a clinician before considering anything.

[8] [7]
Matrix-remodeling and growth-factor pathway activation

Consistently reported across the preclinical literature · Not an adverse effect in itself, but the mechanism is non-specific. GHK modulates matrix metalloproteinase expression and activation in rat wound tissue and in fibroblast culture, and reproduces a transforming growth factor beta gene-expression pattern in human lung fibroblasts. Pathways that remodel tissue and recruit vessels do not distinguish between tissue a person wants rebuilt and tissue they do not, and no study has examined what that means in someone with a fibrotic condition or a history of malignancy.

[2] [3] [10]
Formulation instability and unpredictable delivery

Described as a recurring problem in the topical literature · Reviews of topical GHK describe the peptide as hydrophilic, poorly partitioning, and unstable in formulation, with permeability that varies substantially with the derivative used and with any permeation-enhancing method applied. In practical terms the amount reaching the target layer is not predictable from the amount applied, which makes both benefit and exposure difficult to reason about.

[17] [8]
Unverified identity and purity of unapproved material

Not quantified · With no approved manufacturer, nothing about the composition, copper stoichiometry, or contaminant profile of material labeled GHK-Cu is regulated or independently guaranteed. For a metal complex this matters more than for a bare peptide, because an incorrect copper-to-peptide ratio changes what is actually being delivered. This is a category-level risk that sits on top of whatever the molecule itself does.

[14] [17]

Published lists are never exhaustive, so report anything unexpected to a licensed provider.

Storage, handling & reconstitution

Lyophilized storage: Lyophilized GHK-Cu is a deep blue powder; the color comes from the bound copper(II) ion. It is conventionally kept refrigerated at 2–8 °C, protected from light, with freezing used for long-term holding. The published GHK literature characterizes the peptide's chemistry and copper affinity but does not report vial shelf-life testing, so these handling conventions come from general lyophilized-peptide practice rather than from any GHK-Cu stability study.
Reconstituted storage: Once in solution the complex is conventionally refrigerated at 2–8 °C, protected from light, and treated as short-dated. A 2025 review of topical GHK notes that the peptide is highly water-soluble and chemically unstable in formulation, which is a formulation problem rather than a published solution shelf life. No study establishes one.
Reconstitution diluent: The conventional diluent for lyophilized research peptides, including GHK-Cu, is bacteriostatic water: sterile water preserved with 0.9% benzyl alcohol. Sterile water without preservative is used where a preservative is contraindicated and is treated as single-use. Because the molecule is a metal complex rather than a bare peptide, diluents containing chelators or strong buffers are avoided by convention.
Reconstitution & handling: Conventional handling: sanitize the stopper before piercing it, add the diluent slowly down the inside wall of the vial rather than directly onto the powder, and let it dissolve on its own. Swirl gently if needed; never shake. A properly reconstituted GHK-Cu solution is a clear blue; cloudiness, loss of color, or visible particulate is a reason to discard it. PHL does not publish volume or unit calculations, because those are dosing decisions and dosing decisions belong with a licensed clinician.
Handling notes: GHK-Cu has no FDA-approved manufacturer, so there is no label, no assigned beyond-use date, and no lot-level stability testing standing behind any storage claim. A discolored or precipitated solution is a signal that the copper complex has changed, and everything above is convention rather than specification.

The how-to guides cover the conventions behind these fields, and what the published stability data does and does not establish: Storage, Reconstitution, Handling.

Goal pages that include GHK-Cu

Each one starts from the goal rather than the molecule, and grades what the evidence supports for that goal specifically.

Anti-Aging
A research reference for the compounds mapped to longevity and healthy aging. It sets out what the randomized human trials of oral NAD+ precursors and DHEA actually measured, why the injected forms have no outcomes evidence at all, and where the rest is mice and cell culture.
Hair
A research reference for the compounds people map to hair loss and hair growth, including the finding that the copper-peptide hair study everyone cites tested a different peptide, and that nothing in this library has a published human efficacy result for hair.

Questions for your provider

Bring this page to a licensed provider. A provider can order labs, review your medications and history, and tell you whether anything here is relevant to your situation. This page can't. Peptide Health Lab does not prescribe and does not sell peptides.

Want a structured starting point for that conversation? The Stack Builder turns your goals into a research-cited outline you can review together.

Citations

17 sources · every identifier checked against PubMed

[1] Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ · FEBS Letters, 1988. In vitro study
[2] Expression and activation of matrix metalloproteinases in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ · Journal of Investigative Dermatology, 1999. Animal study
[3] The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures · Life Sciences, 2000. In vitro study
[4] Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu(2+) · Journal of Investigative Dermatology, 2000. Animal study
[5] The effect of topical tripeptide-copper complex on healing of ischemic open wounds · Veterinary Surgery, 2003. Animal study
[6] The effect of tripeptide-copper complex on human hair growth in vitro · Archives of Pharmacal Research, 2007. In vitro study
[7] The human tri-peptide GHK and tissue remodeling · Journal of Biomaterials Science, Polymer Edition, 2008. Review
[8] Human skin penetration of a copper tripeptide in vitro as a function of skin layer · Inflammation Research, 2011. In vitro study
[9] The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health · Oxidative Medicine and Cellular Longevity, 2012. Review
[10] A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK · Genome Medicine, 2012. In vitro study
[11] Stem cell recovering effect of copper-free GHK in skin · Journal of Peptide Science, 2012. In vitro study
[12] GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration · BioMed Research International, 2015. Review
[13] The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline · Brain Sciences, 2017. Review
[14] Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data · International Journal of Molecular Sciences, 2018. Review
[15] Glycyl-l-histidyl-l-lysine-Cu(2+) rescues cigarette smoking-induced skeletal muscle dysfunction via a sirtuin 1-dependent pathway · Journal of Cachexia, Sarcopenia and Muscle, 2023. Animal study
[16] Synergy of GHK-Cu and hyaluronic acid on collagen IV upregulation via fibroblast and ex-vivo skin tests · Journal of Cosmetic Dermatology, 2023. In vitro study
[17] Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective · BioImpacts, 2025. Review

Before you act on any of this

This page is educational only and is not medical advice. It does not diagnose, treat, or prescribe. Review it with a licensed provider before making any health decision. Peptide Health Lab does not sell peptides.

How we grade and verify evidence · Terms of Use · Privacy Policy

Open the Stack Builder